You Can’t Patent LSD

Key takeaways

The psychedelic therapy industry is at a pivotal point, with a few companies advancing into crucial phase three clinical trials.
The clinical trial process for new drugs is lengthy and complex, particularly for psychedelics, which present unique testing challenges.
Regulatory approval processes are evolving, with the FDA showing cautious openness to psychedelics, provided they can prove safety and efficacy.
Investor interest in psychedelic stocks has plummeted since their peak in 2021, but positive developments in clinical trials could change that.
A strategic approach to investing in the psychedelic space should involve incremental investment aligned with clinical progress.

Summary

Current State of the Psychedelic Industry

Ricky Mulvey introduces Keith Speights to discuss the current landscape of the psychedelic therapy industry, highlighting successful companies like Compass Pathways and Sibon, which are in phase three clinical testing. They emphasize that while the risk remains, many of the hurdles have been overcome, enabling a renewed investor interest as positive trial results surface.

Clinical Trials: Processes and Challenges

Speights outlines the extensive clinical trial process to gain FDA approval, beginning from drug discovery to phase one, two, and then three testing. The key questions focus on safety, dosage, and efficacy. The challenges, especially with psychedelics, include the inability to perform double-blind testing, complicating the way results are interpreted.

Regulatory Landscape and Hurdles

The FDA treats psilocybin as any other experimental drug, requiring proof of efficacy without harm. Speights elaborates on the recent FDA guidance aimed at preventing misuse and addressing psychoactive effects. Despite the classification as schedule one substances, the regulatory environment appears to be evolving positively.

Investor Sentiment and Market Dynamics

The podcast delves into the drastic shift in investor sentiment, particularly post-2021 when the psychedelic market peaked, leading to significant downturns for many stocks. Companies like Compass Pathways experienced delays in trials, causing market caps to tumble by over 60%. Speights notes that while caution prevails, investor interest could revitalize with successful late-stage tests.

The Future of Psychedelic Stocks

Looking ahead, Keith Speights outlines his outlook for the psychedelic industry, noting that while it remains highly speculative, successful completion of phase three tests could reignite interest. A strategic investment approach is crucial, balancing risk and reward given the unique challenges in this sector.

Show notes

Mary Long caught up with Motley Fool Contributor Keith Speights to check in on the psychedelic industry. They discuss:
- Advice to investors looking at a highly speculative industry.
- The cash and regulatory questions for these companies.
- Key differences between the cannabis market and psychedelic stocks.
- The challenges of doing a double-blind test on psychedelic compounds.

Companies discussed: CMPS, CYBN, ATAI

Host: Mary Long
Guest: Keith Speights
Producer: Ricky Mulvey
Engineers: Rick Engdahl, Desireé Jones
Learn more about your ad choices. Visit megaphone.fm/adchoices